Daewoong Pharmaceutical
Daewoong Pharmaceutical Co., Ltd., commonly referred to as Daewoong, is a leading South Korean pharmaceutical company headquartered in Incheon, South Korea. Established in 1945, Daewoong has made significant strides in the pharmaceutical industry, focusing on research and development, manufacturing, and marketing of innovative medicines. The company operates extensively across Asia, Europe, and the Americas, with a diverse portfolio that includes prescription drugs, over-the-counter products, and biopharmaceuticals. Notable for its commitment to innovation, Daewoong has developed unique therapies in areas such as gastroenterology, neurology, and endocrinology. With a strong market position, Daewoong has achieved several milestones, including the successful launch of its biosimilar products, which have garnered recognition for their quality and efficacy. As a forward-thinking organisation, Daewoong Pharmaceutical continues to contribute to global health advancements.
DitchCarbon Score
How does Daewoong Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Daewoong Pharmaceutical's score of 30 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Daewoong Pharmaceutical's reported carbon emissions
In 2024, Daewoong Pharmaceutical reported total carbon emissions of approximately 32,460,000 kg CO2e, comprising about 9,675,000 kg CO2e from Scope 1 and about 23,296,000 kg CO2e from Scope 2. This marks a slight decrease from 2023, where emissions were approximately 34,362,000 kg CO2e, with Scope 1 at about 10,184,000 kg CO2e and Scope 2 at about 24,522,000 kg CO2e. The company has consistently disclosed its emissions data for Scope 1 and Scope 2 over the past few years, with 2022 emissions recorded at approximately 34,641,000 kg CO2e, and 2021 at about 32,690,000 kg CO2e. However, there is no available data for Scope 3 emissions, indicating a potential area for future reporting and improvement. Despite the absence of specific reduction targets or climate pledges, Daewoong Pharmaceutical's ongoing commitment to transparency in emissions reporting reflects an awareness of its environmental impact. The company has not yet established science-based targets for emissions reduction, which could enhance its sustainability efforts in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 35,843,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daewoong Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
